Pharmaceutical Executive
How should drug companies and physicians interact? And if something is wrong with the relationship, who's to blame?
How should drug companies and physicians interact? And if something is wrong with the relationship, who's to blame?
Some of the best thinking I've seen on that important issue comes in the British Medical Journal, which devoted most of its May 31 issue to teasing out the complexities of how for-profit drug companies alter medicine's playing field. It's a project that could have fallen into pharma bashing-and some individual pieces come close. But it's saved by a willingness to look past the surface to figure out how the pharma-medical system really works and why.
"This relationship isn't a Manichean battle between good and evil," writes deputy editor Jane Smith, "but the entwinement of individuals from different backgrounds and value sets who get to know, and often to like each other and therefore want, as humans do, to reciprocate friendships and favors."
The contributors don't let pharma off the hook, but they generate some fascinating insights into how the world works-and how hard it is to fix:
The editors may have set out to critique pharma, but by refusing to settle for obvious answers they've begun to sketch the realities of an industry that mixes public and private interests in ever more complex ways. Anything that gives all the players a more realistic sense of what's wrong and how the pieces are connected serves us all.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.